Cargando…

Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist

PURPOSE OF REVIEW: To provide neurologists with an update on the proposed mechanisms of action (MOAs) of disease-modifying therapies (DMTs) for the treatment of relapsing MS, and their effect on peripheral blood leukocytes, in order to inform treatment decisions. RECENT FINDINGS: DMTs have vastly di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fox, Edward J., Buckle, Guy J., Singer, Barry, Singh, Vibhuti, Boster, Aaron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382377/ https://www.ncbi.nlm.nih.gov/pubmed/30859008 http://dx.doi.org/10.1212/CPJ.0000000000000567

Ejemplares similares

Late-Onset MS: Disease Course and Safety-Efficacy of DMTS
por: Buscarinu, Maria Chiara, et al.
Publicado: (2022)

DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
por: Sormani, Maria Pia, et al.
Publicado: (2021)

A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT’s) in multiple sclerosis (MS)
por: de Ceuninck van Capelle, Archibald, et al.
Publicado: (2017)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Immune Response after COVID-19 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
por: Mazziotti, Valentina, et al.
Publicado: (2022)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Lymphopenia in treatment-naive relapsing multiple sclerosis
por: Lim, Zhi Wei, et al.
Publicado: (2016)

Factors Associated with Neurologists' Provision of MS Patient Care
por: Halpern, Michael T., et al.
Publicado: (2014)

Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland
por: Czarnowska, Agata, et al.
Publicado: (2022)

Adults With Complex Congenital Heart Disease: Cerebrovascular Considerations for the Neurologist
por: Smith, Jonathan M. C., et al.
Publicado: (2019)

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives
por: D’Amico, Emanuele, et al.
Publicado: (2016)

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity
por: Sheu, Ting-Ting, et al.
Publicado: (2021)

B-cell–targeted therapies in relapsing forms of MS
por: Dubey, Divyanshu, et al.
Publicado: (2017)

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
por: Comi, Giancarlo, et al.
Publicado: (2019)

Selective adsorption of 1,3-dimethyltrisulfane (DMTS) responsible for aged odour in Japanese sake using supported gold nanoparticles
por: Murayama, Haruno, et al.
Publicado: (2018)

Alienist and Neurologist
Publicado: (1881)

Alumist and Neurologist
Publicado: (1881)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Lymphopenia in SARS
por: Panesar, Nirmal S
Publicado: (2003)

Psychiatrists, Neurologists and the Neurosurgeon
por: Cushing, Harvey
Publicado: (1935)

The Training of the Neurologist and the Psychiatrist
Publicado: (1937)

An Eighteenth Century Neurologist
por: Comrie, John D.
Publicado: (1925)

Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database
por: Sportiello, Liberata, et al.
Publicado: (2023)

Demographics and management of outpatient concussion visits among neurologists and non-neurologists: 2006–2016
por: Asselin, Patrick D, et al.
Publicado: (2020)

Increased leptin and A-FABP levels in relapsing and progressive forms of MS
por: Messina, Silvia, et al.
Publicado: (2013)

Neurologists’ role in antimicrobial resistance
por: Mahboobi, Hamidreza, et al.
Publicado: (2012)

Web resources for neurologists and neurosurgeons
por: Prasad, Murali, et al.
Publicado: (2013)

Palliative care and the Indian neurologist
por: Gursahani, Roop
Publicado: (2016)

Inflammatory myopathies: an update for neurologists
por: Silva, André Macedo Serafim, et al.
Publicado: (2022)

A Neurologist’s Percussion Hammer
por: Krauss, Wm. C.
Publicado: (1895)

Lymphopenia and autoimmune diseases
por: Schulze-Koops, Hendrik
Publicado: (2004)

Do neurologists in Germany adhere to the national Parkinson’s disease guideline?
por: Schröder, Sabrina, et al.
Publicado: (2011)

Functional Neurologic Disorders, disorders to be managed by neurologists, or are neurologists wandering in a dangerous field with inadequate resources?
por: Onofrj, Marco, et al.
Publicado: (2023)

Treatment selection and experience in multiple sclerosis: survey of neurologists
por: Hanson, Kristin A, et al.
Publicado: (2014)

Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
por: Berger, Amnon A., et al.
Publicado: (2021)

Covid-19, the pandemic war: Implication for neurologists
por: de Seze, J., et al.
Publicado: (2020)

Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS)
por: Saposnik, Gustavo, et al.
Publicado: (2017)

Neurologists' understanding and management of conversion disorder
por: Kanaan, Richard A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4094notacq7apdd0fdlug8vorc